18 January 2022 - Federal health authorities have approved a breakthrough drug for ovarian cancer, bringing a game-changing treatment option to women in advanced stages of the deadly disease.

The new drug called Zejula – also known as a PARP inhibitor – will mean women diagnosed with ovarian cancer, who have responded to existing treatments such as chemotherapy and surgery, will now be able to access another level of treatment.

Read The Australian article